Group 1 - The core index, the CESHKB, experienced a decline of 1.62%, closing at 8758.46 points with a trading volume of 12.171 billion [1] - Over the past month, the CESHKB has increased by 21.79%, by 64.09% over the last three months, and has risen 98.69% year-to-date [1] - The CESHKB is designed to reflect the overall performance of biotechnology companies listed in Hong Kong, with a base date of December 12, 2014, and a base point of 2000.0 [1] Group 2 - The top ten holdings of the CESHKB include: CanSino Biologics (13.31%), Innovent Biologics (9.84%), 3SBio (9.12%), BeiGene (8.94%), WuXi Biologics (8.9%), WuXi AppTec (5.65%), Kintor Pharmaceutical (4.91%), Zai Lab (4.82%), Nuo Therapeutics (4.34%), and Kingstar Biotech (4.0%) [1] - The CESHKB is fully composed of stocks listed on the Hong Kong Stock Exchange, with a sector breakdown showing 59.75% in biopharmaceuticals, 23.83% in pharmaceutical and biotechnology services, 14.25% in chemical drugs, and 2.17% in medical devices [2]

Group 1 - The core index of the CSI Hong Kong Stock Connect Innovative Drug Index (931250) experienced a decline of 1.42%, closing at 1114.48 points with a trading volume of 16.63 billion yuan [1] - Over the past month, the index has increased by 22.12%, by 65.37% over the last three months, and has risen 94.38% year-to-date [1] - The index comprises 50 listed companies involved in innovative drug research and development, reflecting the overall performance of innovative drug companies within the Hong Kong Stock Connect [1] Group 2 - The top ten weighted companies in the index include: CanSino Biologics (10.0%), Innovent Biologics (9.88%), BeiGene (8.97%), WuXi Biologics (8.93%), China Biologic Products (7.69%), CSPC Pharmaceutical Group (7.19%), 3SBio (5.66%), Hansoh Pharmaceutical (4.23%), WuXi AppTec (3.5%), and Kelun-Biotech (3.05%) [1] - The index's holdings are entirely composed of companies listed on the Hong Kong Stock Exchange, with a 100% allocation [1] Group 3 - In terms of industry composition, the index's sample holdings consist of 40.89% in drug formulations, 40.00% in other biopharmaceuticals, 18.70% in pharmaceutical and biotechnology services, and 0.41% in vaccines [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December each year [2] - Special circumstances may lead to temporary adjustments to the index, such as delisting of samples or corporate actions like mergers and acquisitions [2]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [2] Core Insights - The pharmaceutical and biotechnology sector has shown a weekly return of 4.00%, outperforming the CSI 300 by 2.91%, ranking second among 31 primary sub-industry indices [3][8] - The report emphasizes the importance of innovation and recovery as key investment themes, highlighting the ongoing enthusiasm for innovative drugs driven by policy incentives and clinical data [10] - Notable mergers and acquisitions, such as China Biopharmaceutical's acquisition of Lixin Pharmaceutical for approximately $1 billion, are seen as significant milestones in the industry [9][10] Summary by Sections 1. Industry Overview - The pharmaceutical and biotechnology sector's monthly return was 9.44%, ranking fourth among 31 primary sub-industry indices, with the medical services sub-sector leading with a 15.72% increase [8][22] - The chemical pharmaceuticals sub-sector had the highest weekly return of 6.86% [32] 2. Market Performance and Valuation - The current PE (TTM) for the pharmaceutical and biotechnology industry is 30.03, which is below the historical average of 30.89 [14][17] - The industry has shown a 21.25% increase over the last six months, outperforming the CSI 300 by 14.79% [12][14] 3. Stock Performance - Top-performing stocks in the past week include Borui Pharmaceutical, Lisheng Pharmaceutical, and Nanxin Pharmaceutical, with increases of 42.35%, 41.68%, and 34.95% respectively [37] - In the Hong Kong market, stocks like Sanofi Biologics and Lepu Medical have also shown significant gains of 63.79% and 62.04% [41] 4. Industry and Company Dynamics - Recent policy developments include the Shanghai Municipal Drug Administration's action plan for regulating online drug sales from 2025 to 2027 [44] - The National Healthcare Security Administration has initiated the eleventh batch of centralized drug procurement, which will include 55 varieties [44]

作者：行情君 从中证香港生物科技主题指数持仓样本的行业来看，化学药占比40.88%、生物药品占比39.81%、制药 与生物科技服务占比16.53%、医疗器械占比2.77%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一个定期 调整日前，权重因子一般固定不变。特殊情况下将对指数进行临时调整。当样本退市时，将其从指数样 本中剔除。样本公司发生收购、合并、分拆等情形的处理，参照计算与维护细则处理。 从指数持仓来看，中证香港生物科技主题指数十大权重分别为：百济神州（13.72%）、信达生物 （12.08%）、药明生物（9.08%）、康方生物（8.04%）、中国生物制药（6.18%）、石药集团 （5.78%）、三生制药（4.55%）、翰森制药（3.4%）、药明康德（2.82%）、科伦博泰生物-B （2.45%）。 从中证香港生物科技主题指数持仓的市场板块来看，香港证券交易所占比100.00%。 本文源自：金融界 金融界7月21日消息，上证指数高开高走，中证香港生物科技主题指数 (港股生物 ...

Investment Rating - The industry investment rating is "stronger than the market," indicating that the industry index is expected to outperform the market by more than 5% over the next six months [56]. Core Insights - The report highlights the rapid pace of the implementation of the 11th batch of national centralized procurement, with 55 varieties included, a decrease of 7 from the previous batch. The average price drop in past procurement batches ranged from 48% to 59% [4][10]. - The total sales scale of the 11th batch of procurement varieties in medical institutions is projected to exceed 49 billion yuan in 2024 [10]. - The report identifies key therapeutic areas for the 55 varieties, including blood and hematopoietic system drugs, digestive system and metabolic drugs, respiratory system drugs, and others, with varying numbers of products in each category [10][11]. Summary by Sections National Procurement Overview - The 11th batch of national centralized procurement includes 55 varieties, with a total of 515 varieties across all batches. The average price drop in previous batches was between 48% and 59% [4][6]. - The timeline from the release of procurement documents to the announcement of selected results is approximately 1-2 months, followed by 3-4 months for implementation [4][7]. Competitive Landscape - Among the 55 varieties, 37 have 10 or more qualifying companies, with 4 having 30 or more. The leading companies in terms of the number of approved varieties include Beite Pharmaceutical, Kelun Pharmaceutical, and Fosun Pharma [10][12]. Changes in Procurement Rules - The report outlines changes in procurement rules for the 11th batch, including reasons for exclusion of certain products, such as low annual procurement amounts and high clinical risks [16][19]. - The reporting method for medical institutions has shifted from generic names to specific brand names for reporting quantities [19]. Sales and Market Share - The report provides a detailed table of the expected sales and market share for various products in the 11th batch, highlighting significant sales figures for products like Dapagliflozin and Olaparib, with market shares reaching up to 100% for some products [24][26]. Investment Strategy - The report suggests focusing on innovative pharmaceutical companies with rich pipeline layouts, such as Heng Rui Medicine and BeiGene, as well as companies with significant single-product potential and leading technology platforms [30].

2025 年 07 月 20 日 投资评级：看好（维持） 医药生物 行业走势图 -24% -12% 0% 12% 24% 36% 2024-07 2024-11 2025-03 医药生物 沪深300 数据来源：聚源 相关研究报告 《CXO 龙头中报业绩超预期，重点关 注板块后续行情 — 行 业 周 报 》 -2025.7.13 《艾伯维收购 Capstan，加码体内 CAR-T—行业周报》-2025.7.6 《多款减肥药亮相 2025 ADA，重点关 注 AMYR 与 ActRII 靶点—行业周报》 -2025.6.29 集采政策明确优化，继续推荐制药板块性机会 ——行业周报 | 余汝意（分析师） | 刘艺（联系人） | 聂媛媛（联系人） | | --- | --- | --- | | yuruyi@kysec.cn | liuyi1@kysec.cn | nieyuanyuan@kysec.cn | | 证书编号：S0790523070002 | 证书编号：S0790124070022 | 证书编号：S0790124050002 | 集采政策持续优化，仿创 pharma 有望估值重塑 集采政策优化基调明确， ...

Group 1 - The core viewpoint of the article highlights the performance and outlook of the China Europe Medical Innovation Fund A, which reported a profit of 467 million yuan in Q2 2025, with a net value growth rate of 9.9% [3][4] - As of July 18, 2025, the fund's unit net value was 1.659 yuan, and it has achieved a one-year compounded net value growth rate of 79.73%, the highest among its peers [3][5] - The fund manager expressed optimism for the third quarter, particularly in the innovative drug sector, citing increasing global collaboration and the expected release of important clinical data [4] Group 2 - The fund's three-month compounded net value growth rate was 46.09%, ranking 7th out of 54 comparable funds, while the six-month growth rate was 66.69%, ranking 12th [5] - The fund's average stock position over the past three years was 89.96%, with a peak of 93.59% at the end of the first half of 2025 [14] - The fund has a high concentration of holdings, with the top ten stocks consistently representing over 60% of the portfolio, including companies like Sangfor Technologies and WuXi Biologics [20]

Group 1 - The Hong Kong Innovative Drug ETF (159567) closed with a gain of 0.56% on July 18, with a trading volume of 2.25 billion yuan [1] - The fund was established on January 3, 2024, with a management fee of 0.50% and a custody fee of 0.10% [1] - As of July 17, 2024, the fund's latest share count was 2.025 billion, with a total size of 3.63 billion yuan, reflecting an increase of 412.28% in shares and 860.92% in size since December 31, 2023 [1] Group 2 - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 79.25% during the management period [2] - The top holdings of the fund include Innovent Biologics, WuXi Biologics, BeiGene, and others, with significant weightings such as 9.52% for Innovent Biologics and 9.47% for WuXi Biologics [2] - The fund's trading liquidity is strong, with a cumulative trading amount of 40.368 billion yuan over the last 20 trading days, averaging 2.018 billion yuan per day [1][2]

Core Viewpoint - The article discusses the opportunities and challenges faced by Chinese enterprises in overseas mergers and acquisitions (M&A) by 2025, highlighting the impact of global trade changes, geopolitical factors, and regulatory compliance on these strategies [2][4]. Summary by Sections Event Overview - The "Chinese Enterprises Overseas M&A Strategy" closed-door exchange meeting was successfully held in Beijing, featuring experts from various fields to discuss the theme of opportunities and challenges in overseas M&A for Chinese enterprises by 2025 [1][2]. M&A Market Insights - In the first half of 2025, the global M&A market showed significant recovery, with a total transaction value of $1.98 trillion, a year-on-year increase of 33%. However, the number of transactions decreased by 10%, indicating that larger deals are dominating the market [7]. - The Chinese mainland's M&A total reached $252 billion, a staggering increase of 130% year-on-year, accounting for 13% of the global market share, with transaction numbers increasing by 13% [7]. Challenges in Overseas M&A - Chinese enterprises face complex acquisition processes and diverse stakeholder demands, particularly in Southeast Asia, where legal systems vary significantly and foreign investment restrictions exist [5][6]. - Regulatory challenges include the need for compliance with new policies, such as the "M&A Six Guidelines," which have increased regulatory inclusivity but also present operational ambiguities [11][12]. Strategic Innovations - Companies are adopting innovative strategies to navigate global trade tensions, such as "nearshore manufacturing + local delivery" and brand acquisitions to mitigate tariffs [14]. - The introduction of geopolitical due diligence systems and digital tools for real-time monitoring of tariff policies is helping companies shorten decision-making cycles by an average of 35% [14]. Future Investment Strategies - Chinese enterprises are employing a three-dimensional investment framework to adapt to a fragmented global landscape, focusing on resilience, symbiotic logic, and innovative approaches [16]. - The differentiation in overseas direct investment (ODI) is evident, with Asia accounting for 52.3%, Europe 19.8%, and Africa 13.1% of the total investment, reflecting targeted sectoral strategies [16].

Core Insights - The report highlights the significant growth potential in the measurement and calibration industry, driven by new policies aimed at enhancing manufacturing capabilities in China [6][7][8] - The renewable energy sector, particularly in electric power equipment, is poised for growth due to supportive policies in the UK and increasing demand for energy storage solutions [13] - The pharmaceutical industry is recommended for investment, focusing on innovative drugs and their supply chains, with strong support from health insurance reforms [14] Industry and Company Analysis - **Measurement and Calibration Industry**: The first policy document from the Ministry of Industry and Information Technology emphasizes the need for precise measurement to drive innovation in manufacturing. This includes establishing a service network and digital transformation paths, with a focus on high-level calibration institutions and digital measurement software [6][7] - **Renewable Energy Sector**: The UK government has restarted subsidies for electric vehicles and charging infrastructure, indicating a robust market for energy storage systems. The report suggests focusing on companies involved in battery production and charging infrastructure, such as Ningde Times and Keda Technology [13] - **Pharmaceutical Industry**: The report continues to recommend innovative drug sectors, highlighting the recent adjustments in health insurance and commercial insurance that favor high-value innovative drugs. Companies like Kelun-Biotech and Innovent Biologics are noted for their strong potential in both domestic and international markets [14] - **Oil and Gas Sector**: China National Offshore Oil Corporation (CNOOC) has made significant advancements in oil and gas exploration, achieving record production levels in both domestic and international operations. The report anticipates continued growth in production capacity, particularly in the Stabroek block in Guyana [20][21][24]